image

Host: Gerald Lee, MD, FACAAI
Experts: Brian P. Vickery, MD; Edwin H. Kim, MD, FACAAI Disclosures

Recorded 12/03/2025

Learning Objectives:

  1. Distinguish between IgE-mediated and non-IgE-mediated food allergies and food intolerances.
  2. Apply current evidence-based guidelines for early food allergy prevention and diagnosis.
  3. Describe the clinical application of oral, sublingual, and epicutaneous immunotherapy for food allergy.
  4. Evaluate the role of biologic therapies, such as omalizumab, in the management of complex or refractory food allergy cases.

This episode is not eligible for CME.


To download the mp3 file, right click on the player and select Save audio as.

Show Notes:

Food allergy is a complex and potentially life-threatening condition that requires a multidisciplinary approach to diagnosis, prevention, and treatment. Yet confusion persists among clinicians regarding the accurate identification and management of food allergies, particularly in differentiating between IgE-mediated reactions, non-IgE-mediated allergies, and food intolerances. Simultaneously, rapid advancements in therapy—including immunotherapies and biologics—are creating new opportunities for proactive and personalized care.

During this episode we were joined by Dr. Brian Vickery and Dr. Edwin Kim. Dr. Brian Vickery is Professor of Pediatrics and Chief of the Division of Allergy/Immunology at Emory University and Children’s Healthcare of Atlanta. A nationally recognized clinician-scientist, his research focuses on improving outcomes for children with food allergies through novel interventions and therapies. He has authored over 125 publications and is a leading voice in advancing the field of pediatric food allergy. Dr. Edwin Kim is an associate professor of pediatrics and chief of the division of pediatric allergy and immunology at the University of North Carolina School of Medicine. He also directs the UNC Food Allergy Initiative research group whose focus is the development of novel therapeutics for food allergy.

For more information on this topic, please visit:

Anagnostou A, Abrams EM, Carver M, et al. Development and acceptability of a decision-aid for food allergy oral immunotherapy in children. Allergy. 2025;80(1):205-214. doi:10.1111/all.16332

Anagnostou A, Greenhawt M, Shaker M, Vickery BP, Wang J. Food allergy yardstick: Where does omalizumab fit?. Ann Allergy Asthma Immunol. 2025;134(1):110-121. doi:10.1016/j.anai.2024.07.034

Bartha I, Almulhem N, Santos AF. Feast for thought: A comprehensive review of food allergy 2021-2023. J Allergy Clin Immunol. 2024;153(3):576-594. doi:10.1016/j.jaci.2023.11.918

Dantzer J, Virkud Y, Wang J, et al. Introduction of allergenic foods after treatment with omalizumab. J Allergy Clin Immunol. 2025;156(2):394-405. doi:10.1016/j.jaci.2025.05.014

Wood RA, Togias A, Sicherer SH, et al. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024;390(10):889-899. doi:10.1056/NEJMoa2312382

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion!

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Speaker Disclosures: back to top

Gerald Lee, MD, FACAAI
Nothing relevant to disclose.

Brian P. Vickery, MD
Nothing relevant to disclose.

Edwin H. Kim, MD, FACAAI
Nothing relevant to disclose.

This podcast miniseries is supported by Genentech.